Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction

• Status: Unknown status
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study is designed to confirm the therapeutic effects of heat-clearing and blood-activating Chinese medicinal components in treatment of Acute Cerebral Infarction (ACI) and to investigate the therapeutic mechanisms of multi-target anti-inflammatory action involved from the standpoint of pathology, cell and molecular biology, as well as immunology.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yunling Zhang
• Collaborators: Huairou Hospital of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Wuqing Hospital of Traditional Chinese Medicine

Criteria

Inclusion Criteria:

• Patients with acute ischemic stroke

• Patients with fire-heat syndrome

• Stroke onset within 48 hours

• NIHSS scores range from 5 points to 25 points

• Age from forty to eighty,gender not limited

• Informed and signed the consent

Exclusion Criteria:

• Cardiogenic cerebral embolism,stroke caused by other reasons or the unexplained

• Patients suitable for thrombolytic therapy(rt-PA,urokinase),or have recieved thrombolytic therapy

• Patients suitable for endovascular therapy,or have recieved endovascular therapy

• Patients with serious disease of heart,lungs,liver or kidneys（The value of ALT or AST is more than 2 times of the upper limit of normal range,the value of creatinine is more than 1.5 times of the upper limit of normal range，asthma or COPD,or cardiac function level 4）

• Patients with bleeding or bleeding tendency recently

• Pregnant or lactating women

• Pre-existing limb dysfunction, psychiatric diaseses，or cognitive dysfunction that could confound the study results

• Patients with allergic constitutions,or have the contraindication of Ixeris of sonchifolia Hance components(KDZ injection) or Panax notoginseng saponins components(Xueshuantong injection)

• Patients have participated in other clinical trials within 3 months